OnKure Therapeutics (OKUR) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($99.7 million vs $97.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKUR | PLYX |
|---|---|---|
| Share price | $2.41 | $2.00 |
| Market cap | $97.60M | $99.69M |
| 1-day change | +4.78% | 0.00% |
| YTD return | -16.90% | — |
| 1-year return | -23.00% | — |
| 5-year return | -96.26% | — |
| EPS (TTM) | $-3.20 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.38 | $48.91 |
| 52-week low | $2.13 | $1.85 |
| Distance from 52-week high | -55.20% | -95.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +543.15% | +275.00% |
| Average volume | 216.96K | 76.41K |
| Shares outstanding | 40.50M | 49.85M |
| Employees | 45 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
OKUR vs PLYX FAQ
Which is bigger, OnKure Therapeutics or Polaryx Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $99.69M compared with $97.60M for OnKure Therapeutics (OKUR).
Are OnKure Therapeutics and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.